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Non-traditional antimicrobials have been an area of great interest due to the 
increasing prevalence of antimicrobial resistance (AMR) in bacteria. Antimicrobial 
peptides (AMPs) & ionic liquids (ILs) are two examples that have been investigated as a 
potential solution. Most AMPs are naturally derived & exhibit high selectivity against 
bacterial targets over host cells. The venom-derived peptide, ponericin L1 from 
Neoponera goeldii, was used to investigate the role of cationic residues & net charge on 
peptide activity. Using both in vitro & microbiological methods, L1 peptide & derivatives 
exhibited an α-helical conformation with enhanced binding to lipid vesicles containing 
anionic lipids & low hemolytic activity. Net charge & identity of the cationic groups on 
the peptide were shown to play a significant role in antimicrobial activity. ILs have also 
been investigated in combination with antimicrobial compounds to fight AMR. 
Imidazolium chloride-based ILs with differing alkyl tails & commercially available 
antibiotics were used to examine the potential for synergistic effects on multiple bacteria. 
Analysis of the IL data indicates that length of the alkyl chain play a crucial role in 
antimicrobial activity & cytotoxicity. A synergistic effect was exhibited while showing 
low cytotoxicity when tested in a mammalian cell culture model.  
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Overview of Antimicrobials 
Background 
History of antimicrobials. For thousands of years, infections had reached 
epidemic proportions costing the lives of millions [1]. There have been many 
interventions throughout time to prevent and control the spread of infection. For example, 
in 1846, a Hungarian physician, Semmelweis, found that mortality from childbed fever in 
women who delivered babies by midwives was lower than those delivered by physicians. 
Semmelweis concluded that this issue was a result of cadaverous materials on the hands 
of medical students who came from the autopsy chamber to the obstetric clinic. This led 
to the implementation of hand washing in a chlorinated lime solution before having 
contact with patients, dropping the mortality rate among women that were being cared for 
by physicians [2].  Another groundbreaking discovery occurred in 1928, when Alexander 
Fleming found the first antibiotic, penicillin [3-4]. Then, the discovery that bacteria could 
be isolated, cultured and act as a bioactive molecule was identified. In 1941, the term 
antibiotic was first used by Selman Waksman to describe any small molecule produced 
by a microbe that prevents the growth of another microbe [5]. Multiple antibiotic classes 
with different targets were discovered and soon an assembly line production of penicillin, 
streptomycin, chloramphenicol, and tetracycline were the segue to the antibiotic age 
(1945-1955).  
Discovery, commercialization, and routine administration of antibiotics has 
become one of the most important medical interventions to treat infectious diseases [6].  
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Millions of lives have been saved due to antibiotics [7]. Although, antibiotics are known 
to save lives, the over-prescribing have arguably led to the epidemic of multi-drug 
resistant (MDR) microbes [8]. The capability for multiple types of bacteria to rapidly 
develop mechanisms of resistance to common medications threatens the prevention and 
treatment for infections. Antimicrobial resistance (AMR) has become a major health 
threat globally due to an increased mortality rate in people with a multi-drug resistant 
bacterial infection [9]. 
When treating a multi-drug resistant (MDR) infection, even some of the most 
potent antibiotics are unable to kill these “superbugs” [4]. With delayed development of 
new antibiotics [10], there is an urgent need for novel antimicrobial strategies and/or 
alternative drugs to revive the potency of traditional antibiotics, prevent mortality, and 
help reduce the chances of antimicrobial resistance [11]. An example of a new 
antimicrobial drug is antimicrobial peptides (AMPs). AMPs are a growing class of 
naturally derived novel antibacterial molecules with unique antimicrobial mechanisms. In 
various organisms such as plants, animals, and humans, AMPs contain important 
components for the innate immune system, which become the first-line defense against 
an infection [12-13].  
History of antimicrobial peptides. In 1939, Dubos isolated tyrothricin, an 
antimicrobial agent, from a spore-bearing soil Bacillus strain, which protected mice from 
a pneumococci infection [14]. This led to the first discovery of an AMP named 
gramicidin [15]. Although toxicity was associated with intraperitoneal application, 
gramicidin was effective in treating wounds and ulcers topically [16]. Another AMP 
extracted from tyrothricin, tyrocidine, was discovered in 1941, and exhibited 
3 
 
antimicrobial activity against both Gram-negative and Gram-positive bacteria [17]. 
Although tyrocidine was effective against bacteria, strong hemolytic activity was also 
shown, making it a poor choice for a therapeutic [18]. Later that year, purothionin was 
isolated from the plant Triticumaestivum and was effective against some pathogenic 
bacteria, along with fungi [19]. In 1956, the first animal isolated AMP was a defensin 
found in rabbit leukocytes [20]. Defensins are the largest class of mammalian AMPs and 
have been found throughout evolution. They play a key role in the innate immune 
response to infection, as well as being implicated in wound healing and immune 
modulation [180].  
As of 2016, there have been over 23,000 AMPs discovered including both natural and 
synthetic [21]. Natural AMPs have been found in various sources such as bacteria, 
invertebrates, vertebrates, and plants [22]. AMPs extracted from animals are mainly 
found in the tissues and organs exposed to airborne pathogens to stop most infections 
before symptoms develop [23], [24]. There are various types of eukaryotic cells involved 
in the production of AMPs including epithelial cells in gastrointestinal and genitourinary 
systems [25-26], phagocytes [27], and lymphocytes of the immune system [28-29]. Frog 
skin, for example, contains over 300 different AMPs [30-31]. An example of an AMP 
extracted from the ventral skin of the frog, Xenopus laevis, is called magainin [32]. 
Magainins are produced by the mucous glands in the skin of the frog and exhibit broad-
spectrum antimicrobial activity against bacteria, fungi, and protozoa [33]. 
Structures and characteristics of antimicrobial peptides. AMPs are normally 
amphipathic, cationic peptides with a varying amino acid chain of about five to less than 
50 exhibiting an overall positive charge. AMPs have shown interaction with a broad 
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spectrum of organisms, such as bacteria, including multi-drug resistant bacteria [34], 
cancer [35], viruses [36], fungi [37], and even parasites [38]. They have also been shown 
to rapidly kill cells in seconds after initial contact with their target [39]. 
Based on their secondary structure, AMPs are characterized as α-helix, β-sheet, 
extended, and loop, with α-helix and β-sheet AMPs being the most common [40]. The α-
helical peptides are cationic and amphipathic with some level of hydrophobicity that 
possess antimicrobial activity [41]. Some α-helical AMPs are rich in the amino acids, His 
and Trp. Examples of α-helical AMPs are protegrin, magainin, and LL37 (a human 
cathelicidin) [42]. AMPs classified under β-sheet contain at least two β-strands with 
disulfide bonds between the strands [43]. Although most AMPs belong to one of the four 
categories listed above, some do not belong to any of them [44], and can contain two 
different structural components [45]. Among the four categories of AMPs, the α-helical 
AMPs are one of the most studied types [46].  
Mechanism of action of antimicrobial peptides. Most peptides only form their 
active structure once they are interacting with their target membranes. Commercially-
available antibiotics target specific cellular activities, while AMPs are proposed to use a 
multitude of complementary actions to cause cell death [47]. AMPs kill target cells by 
disrupting the membrane integrity by inhibiting proteins, DNA and RNA synthesis, or by 
interacting with specific intracellular targets. Due to their multi-hit mechanism, this 
reduces the possibility of bacterial drug resistance in AMPs ultimately increasing the 
efficiency of AMPs [48].  
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AMPs initial interaction with the bacterial cell membrane occurs through electrostatic 
bonding between the positively charged peptide and negatively charged components 
located on the outer bacterial envelope [49]. Since AMPs are composed of cationic and 
hydrophobic residues, there is a strong interaction with a bacterial membrane that 
contains negatively charged lipids such as phosphatidylglycerol or cardiolipin [50]. The 
most common explanation of AMPs selectivity for bacterial cells over host cells are the 
difference in membrane interactions caused by the exposed anionic lipid content present 
in bacterial membranes [3]. Since electrostatic interactions play a key role in the binding 
of AMPs to bacterial membranes, the interactions with the neutral 
phosphatidylcholine/cholesterol-rich surfaces of prokaryotic membranes are significantly 
weaker.  
Although the mechanism of action for AMPs are not fully understood, there are many 
proposed pathways to disrupt the bacterial cell membrane that AMPs use. A few models 
include the barrel-stave pore, the toroidal pore, and the carpet model [51]. In the barrel-
stave pore model, peptides are shown interacting laterally with one another to form a 
structure similar to a membrane protein ion channel, while in the toroidal pore model 
peptide-peptide interactions are not present. Instead, the peptides induce a curvature of 
the bilayer to create a high curvature form. The major difference between these two 
models are that the barrel-stave pores are working with the bilayer hydrocarbon core, 
ultimately using it as a template for peptide-self-assembly, while the toroidal pores are 
working against the core, disrupting the segregation of the polar and non-polar parts, to 
provide a surface where lipid hydrocarbons and headgroups are able to interact favorably 
[50]. The carpet model was proposed in 1996 by Shai to explain the mechanism of action 
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of a mammalian cecropin P1 on model membranes. Their proposed model consists of the 
peptide micelle coating a small area of the membrane surface where AMP molecules 
penetrate the lipid bilayer, letting pore formation occur [52]. This method leaves behind 
holes or pores in the membrane [53]. The AMP is only active when aggregation of 
peptides align (to form a carpet-like structure) with the lipid bilayer [54].  
Physiochemical properties of antimicrobial peptides. Since AMPs are composed 
of amino acids, modification to their sequence is relatively easy to perform, which helps 
to modify activity and target spectrum, along with improving stability of AMPs [55-56]. 
Important physiochemical properties of AMPs for their antimicrobial activity and target 
specificity include size, net charge, hydrophobicity, amphipathicity, and solubility [46]. 
Length is an important factor in AMPs because when forming an amphipathic structure 
with hydrophobic and hydrophilic faces on opposite sides, at least 7-8 amino acids are 
needed. Although length effects its 3D structure and potential mode of action, it may also 
affect its cytotoxicity [57]. A study showing a shortened melittin with 15 residues at its 
C-terminal exhibited at least 300 times less toxicity to rat erythrocytes, compared to its 
original form [58]. In another study, a derivative of HP-A3, with deletion of the N-
Terminal random coil (residues 2-5; called A3-NT) exhibited higher antimicrobial 
activity with no hemolytic activity even at high concentrations of peptide [59]. These 
examples show length should be considered while designing a low toxicity synthetic 
peptide.  
The sum of all charges of ionizable groups of the peptide is known as the net charge. 
The charge can vary from negative to positive but is the main factor for initial interaction 
between negatively charged bacterial cell membranes. Most α-helical cationic AMPs 
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contain at least a net positive charge of at least +2 [181].  Many studies have shown net 
charge can affect the AMPs hemolytic and antimicrobial activities, to selectively kill 
microbes with minimal effects on the host cells [4]. For example, a study performed by 
Dathe et al. showed that an increase in net charge of magainin 2 from +4 to +5 increased 
antimicrobial activity. However, an increase to +7 did not increase the observed 
antimicrobial activity but did increase hemolytic activity [182].  
Hydrophobicity has also shown influences the activity and selectivity of AMPs. 
Natural AMPs contain about 50% hydrophobic residues in its sequence. It has been 
shown that when the hydrophobicity increases on the positively charged side of an AMP 
below a threshold can increase its antimicrobial activity, and when hydrophobicity is 
decreased it reduces the antimicrobial activity [42, 60]. There have also been studies 
showing that hydrophobic residues play an important role in hemolytic activity [183]. For 
example, a study performed by Chang et al.showed peptides containing hydrophobic 
residues of N-terminal hydrophobic core were involved in the hemolytic and bactericidal 
activity. When they increased the hydrophobicity in the peptides tested, both bactericidal 
and hemolytic activity was reduced. AMPs do have an optimal window of 
hydrophobicity, and once passed it has a rapid decrease in activity [61].  
Another important property of AMPs is amphipathicity. This helps ensure activity 
and interaction with bacterial cell membranes. A study performed by Fernandes-Vidal et 
al. had shown amphipathicity helps create a strong partition for the AMP to get into the 
membrane interface [62]. This makes amphipathicity more important than hydrophobicity 
when binding to bacterial cell membranes.  
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AMPs solubility in aqueous environments are essential due to initial interactions with 
the bacterial membrane. If the AMP molecules aggregate, it will lose its ability to interact 
with the bacterial cell membrane, making solubility an important factor. Each of these 
properties, length, net charge, hydrophobicity, helicity, amphipathicity, and solubility 
should be taken into consideration when designing a novel peptide. AMPs have evolved 
to balance each of these properties to maintain optimal function. 
Modifications to antimicrobial peptides. There are many factors that affect the 
activity of AMPs. It has been shown that modification of an AMPs properties can alter 
other properties. Even a small change in the primary sequence has been shown to affect 
physiochemical properties necessary for the activity of an AMP to interact with its target 
cell [46]. Although many AMPs are directly synthesized in their active forms, some 
AMPs require post-translational modification to perform their intended functions.  
Venom-derived antimicrobial peptides. A particular category of AMPs that have 
been studied and modified, are venom-derived peptides. Venoms contain a mixture of 
peptides, proteins, and enzymes serving as either predation and defense against microbes 
and predators [63]. Although there are many venom-derived peptides that have 
antimicrobial activity, not all peptides are AMPs or even biologically active when 
extracted. Venoms are comprised of a diverse array of different biologically active 
peptides with a myriad of activities and targets including neurotoxins, membrane 
permeabilizing agents, and GPCR agonists and antagonists [64-65]. In fact, venom 
peptides appear to have evolved from a somewhat small number of structural frameworks 
that are well suited to addressing the crucial issues of potency and stability [65]. These 
bioactive peptides are small in size, relatively easy to synthesize in the lab, and have 
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significant structural stability and target specificity making them a novel antimicrobial 
component [66].  
To survive chemical degradation in solution at ambient temperature and enzymatic 
degradation by processing proteases present in venom, these venom-derived peptides 
must be sufficiently stable [67]. Post-translational modifications (PTMs) and/or disulfide 
bonds is how these peptides are able to achieve this type of stability. Common PTMs 
include amidation (C-terminal), sulfation (Tyr), bromination (Trp), glycosylation (Thr), 
γ-carboxylation (Glu), hydroxylation (Pro), pyroglutamation, N-C-cyclization, and 
isomerization to ᴅ-amino acids [65]. These modifications introduce specific enzymes at 
particular locations during the production of venom peptides, which can help enhance 
bioavailability and potency along with stability. Although many of these modifications 
help enhance peptide properties, they are not always optimal for the requirements 
associated with potential therapeutic applications. Issues such as formulation, cost of 
production, stability, selectivity, and mechanism of action are associated with using 
venom peptides as therapeutics.   
A significant issue with venom peptides is their bioavailability, which is generally 
poor due to their size (10-40 amino acids) and hydrophilic nature [65]. This issue makes 
it necessary for the peptide to be administered to the site of action by injection 
(intravenous, intrathecal, intraperitoneal, intramuscular, subcutaneous, or epidural). There 
have been many emerging approaches, such as lipophilic modifications, to improve 
peptide delivery to help eventually allow oral delivery to central and peripheral target 
[68]. Venom-derived peptides overall have beneficial properties such as stability, and 
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target specificity which are useful in antimicrobial use. However, issues including safety, 
pharmacokinetics, and delivery would need to be addressed before therapeutic use.   
Background of ionic liquids. In addition to discovering new antimicrobials, there 
have been also studies performed to enhance antimicrobial efficacy with commercially 
available antibiotics in combination with other molecules. An example of a widely used 
combinatorial formulation is amoxicillin with clavulanic acid [69]. The amoxicillin is 
used to inhibit peptidoglycan synthesis while clavulanic acid inhibits the β-lactamase 
enzyme which degrades amoxicillin. Other approaches take two molecules that 
independently exhibit antimicrobial activity and combine the dose for treatment [70-71]. 
The majority of combination therapies are designed to act via different mechanisms, 
ultimately enhancing the activity of the other. Unfortunately, no clear best practice using 
these therapies have emerged, only case-specific protocols.  
Ionic liquids (ILs) are a class of salts that exist in liquid form at room temperature 
[72-73]. ILs contain a cation and anion pair which can be changed, creating a wide range 
of IL species. Chemical properties of ILs include low melting point, negligible vapor 
pressure, and exceptional solvation potential. ILs have received attention as a potential 
biomaterial that can undergo modification (via changing their cations and anions) for 
various biomedical applications [74-75]. Other applications of ILs include use in 
pharmaceutics and medicine [76], and the extraction and separation of biomolecules [77]. 
Studies have also shown ILs ability to both stabilize and destabilize protein structures, 
exhibit sensitive protein interactions, enhance enzymatic activity, and impact DNA 
structure [78-80]. However, literature indicates that not all ILs behave similarly and that 
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the effects on biomolecules are dependent on the molecular identity of the components of 
the ILs.   
Ionic liquids as antimicrobials. The interactions between ILs in aqueous 
solution and lipid bilayer membranes have helped guide the development of IL-based 
drug formulation and drug-delivery applications [76, 81-84]. Ultimately opening research 
avenues for IL-based antibiotics and antibiotic-IL combinatorial therapies. There have 
also been reports highlighting both experimental and computational studies on how ILs 
interact with lipid bilayers [85-86]. Hydrophobic ILs are able to insert themselves into 
lipid bilayers, leading to bilayer reorganization [87-89]. ILs have also exhibited 
antimicrobial effects with addition of enzyme-hydrolyzing groups, alkyl chains, and 
stable anions [90]. Additionally, a tetracycline-based IL has been shown to insert into 
liposome membranes with important drug-delivery and antibiotic implications [83].  The 
highly recombinant nature of ILs makes amenable to formulating “designer” reagents to 
treat specific cell types: rearranging both the anion and cation a can allow for highly 
specific, tailored applications in different organisms [82]. Previous studies demonstrated 
that IL with imidazolium-based cations were successful in permeating the membranes of 
bacteria, yeast, and red blood cells [91]. Other ILs have been shown to exhibit 
antimicrobial activity alone, or impact the manner in which antimicrobials interact with 
lipid bilayers [92]. Additionally, micelle formation can occur in these molecules through 
the interactions of the IL alkyl chains, which can influence the interactions with cellular 
membranes [93].   
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Chapter 2  
Investigation of the Sequence-Structure-Activity Relationship in Ponericin L1 from 
Neoponera goeldii 
Introduction 
There are three categories of insect AMPs; Cecropins, Defensins, and peptides 
with an overrepresentation of Proline and/or Glycine residues [94]. They are 
separated based on their amino acid sequence and structure. Cecropins are linear 
peptides that lack cysteine residues but form an α-helix structure. Defensins consist of 
6-8 conserved cysteine residues, are stabilized by 3 or 4 disulfide bridges and contain 
3 domains that have a flexible amino-terminal loop. Cecropins are shown to exhibit 
antimicrobial activity against both Gram-positive and Gram-negative bacteria, while 
Defensins selectively kill Gram-positive, and glycine-rich and proline-rich kill Gram-
negative strains [95]. Insect AMPs are considered very potent due to their IC50 range 
being in the submicromolar or even low micromolar range, even though there are 
none yet on the market [96]. Ponericins have been known to be one of the most 
explored insect AMPs, along with cecropins, drosocin, attacins, diptericins, defensins, 
drosomycin, and metchnikowin [97-98].  
Background on ponericins. Ponericins are AMPs that were isolated from the 
venom of the predatory ant Neoponera goeldii (previously misclassified as 
Pachycondyla goeldii). There are fifteen novel ponericins extracted that exhibit both 
antibacterial and insecticidal properties [99]. Ponericins are classified as either G, W, 
and L based on their primary structure. All three classes are cationic, amphiphilic 
peptide sequences, with nearly all (12/15) containing a Trp residue in the N-terminal 
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region. Ponericins share high sequence similarities with known peptides; the G 
ponericins are like cecropins, W ponericins have similarities with gaegurins and 
melittin, and finally, L ponericins are similar to dermaseptins. All ponericins exhibit 
an α-helical structure in cell membranes [100]. 
The G family of ponericins share about 60% sequence similarity with cecropins. 
Cecropins exhibit broad spectrum antimicrobial activity against bacteria and fungi 
without affecting host cells [101-102]. The W family of ponericins have common 
properties due to their high sequence similarities. They are active against bacteria and 
yeast but also show hemolytic and insecticidal activities. Ponericins W have about 
70% similarity in sequence to gaegurin 5 and melittin. Both the ponericin G and W 
families contain a Pro residue near the middle of the sequence in 11 of 13 sequences 
(the others G6 and G7 have the Pro residue near the C-terminus due to the shorter 
overall length). There have been studies performed on both G- and W-families of 
ponericins [103-108], along with novel peptides that show similarity to the G- and W-
families [109-111]. 
The L-family ponericins, are the most poorly understood peptides and consist of 
ponericin L1 and L2. Both L1 and L2 share sequence similarities with dermaseptin 3 
and 5 [112-114]. The only report of the activity and characteristics of these peptides 
are found in the original report by Orivel et al., and even in this study, only ponericin 
L2 was examined. Ponericin L2 was shown to have broad-spectrum antibacterial 
activity with no hemolytic activity. The peptide adopted a random coil conformation 
in water (possibly polyproline-II helix). Ponericin L1 differs from L2 by only a single 
amino acid at position 9, with L1 containing a Met while L2 contains an Ile. There is 
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a general lack of understanding and investigation of the L-family of ponericins and 
their mechanism.  
Role of cationic groups in AMPs. The cationic charge of an AMP is a key 
component in the initial binding between the peptide and the bacterial cell membrane 
[115]. However, many studies have shown that the position of cationic and 
hydrophobic residues can significantly impact the selectivity and antimicrobial 
activity of AMPs [116-120]. Therefore, the role of cationic residues in context of 
specific hydrophobic amino acids may also have an impact on activity. Cationic chain 
length tolerance may also be influenced by corresponding hydrophobic molecules’ 
size and shape. This study focuses on the characteristics and behavior of ponericin L1 







Figure 1. Peptide Sequences and Helical Wheel Diagrams. Helical wheel diagram of L1, 
A, L1-Q, B, and L1-K, C. Cationic residues are shown in blue, anionic in red, 
hydrophobic in green, polar uncharged in yellow, and aromatic are in purple. Peptides 
sequences and relevant properties are shown below the helical wheels. Helical wheel 




Materials and Methods 
Peptide preparation. Peptides L1-Q, L1-K, and L1-O (ornithine) were 
synthesized using standard FMOC-chemistry in-house. Peptide L1-R was purchased from 
Genscript (Piscataway, New Jersey). The peptide L1-X (L1 with lysine replaced with di-
amino-propionic acid, Dap) presented significant synthetic challenges and was thus 
purchased from Synthetic Proteomics (Carlsbad, California) along with the L1 parent 
sequence. All peptides were subsequently purified via RP-HPLC using a Zorbax C3 
column and eluted by a linear gradient of water to acetonitrile (both supplemented with 
0.1% TFA). Peptide identity was confirmed using ESI-MS. HPLC fractions containing 
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peptide were pooled, lyophilized, and stored at −20°C. Prior to use, peptides were 
dissolved in 3:1 H2O:ethanol to create a stock solution of 150 to 200 μM and stored at 
4°C.  
Lipid preparation. Lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; 
PC), 1,2-dioleoyl-sn-glycero-3-phospho-(10 -rac-glycerol) (DOPG; PG), and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE; PE) were purchased from 
Avanti Polar Lipids (Alabaster, Alabama), and stored as stocks in chloroform at −20°C. 
Lipids were prepared as 100% DOPC, 3:1 DOPC:DOPG (PC:PG), or 3:1 POPE:DOPG 
(PE:PG). Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Chem-Impex Int'l INC.), ortho-
nitrophenyl-β-galactoside (ONPG) (Research Products International Co.), nitrocefin 
(Biovision, Milpitas, California). All other chemicals and reagents were from Thermo 
Fisher Scientific (Waltham, Massachusetts), VWR (Radnor, Pennsylvania), or Sigma-
Aldrich (St. Louis, Missouri). Small unilamellar vesicles (SUVs) were formed by 
sonication or by ethanol dilution methods. In all cases, appropriate volumes of lipids in 
chloroform were mixed in a glass test tube, dried under a gentle stream of N2, and further 
dried under vacuum for at least 1 hour to create a lipid film in the tube. For the ethanol 
dilution vesicles, 10 μM of pure ethanol was added to the film, vortexed until the film 
was dissolved at which point the appropriate amount of PBS was added while vortexing. 
For sonicated vesicles, the PBS was added directly to the lipid film and vortexed to create 
multilamellar vesicles (MLVs). This MLV suspension was then subjected to sonication in 
a high-powered bath sonicator (Avanti Lipids) for 20 minutes to create SUVs. 
Fluorescence spectroscopy. All fluorescence spectroscopy was performed on a 
JY-Horiba Fluoromax4 instrument with excitation and emission slit widths at 2.5 nm. 
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Measurements were taken in semi-micro quartz cuvettes. Spectral barycenters were 
calculated using the following formula: B = Pλ i Pi ð1Þ where B is the barycenter, λ is 
the wavelength, and i is the intensity at that wavelength. The summation is carried out 
over the entire emission spectrum collected, in this case 300 to 400 nm.  
Binding experiments. Lipid binding assays were carried out as performed 
previously [122]. Briefly, the samples contained 2 μM peptide in PBS buffer (150 mM 
NaCl, 50 mM Na2HPO4; pH 7.0) and were titrated with a lipid vesicle stock (0.5 or 1.0 
mM concentration). All binding assays used excitation at 280 nm and an emission range 
of 300 to 400 nm. The spectra were corrected from the background and the dilution after 
each addition.  
Red-Edge Excitation Spectroscopy experiments. Red edge excitation shift 
(REES) experiments used excitation at 280, 290, 295, 300, 305, and 307 nm with an 
emission range of 310 to 410 nm. Again, samples contained 2 μM peptide in PBS buffer. 
The spectra were corrected from the background and the dilution after each addition.  
TCE quenching. Trichloroethanol (TCE) quenching assays were performed by 
titrating 10 μL aliquots of 10 M TCE (Alfa Aesar, Haverhill, Massachusetts) into samples 
containing 2 μM peptide in PBS (150 mM NaCl, 50 mM Na2HPO4; pH 7.0). The Trp 
fluorescence emission was recorded after each addition with excitation at 280 nm and 
emission at 340 nm. Data were corrected from background and dilution. The Stern-
Volmer quenching constant (Ksv) was determined from the slope of a linear best fit 
equation to the data.  
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Acrylamide quenching. Acrylamide quenching was performed by titrating 10 μL 
aliquots of 4 M acrylamide and measuring Trp emission after each addition. Samples 
contained 2 μM peptide and 250 μM total lipid in PBS. The Trp fluorescence emission 
was recorded after each addition with excitation at 295 nm and emission at 340 nm. Data 
were corrected for background, dilution, and inner filter effects in the excitation path as 
described previously [123]. The Ksv was calculated as above.  
DQA experiments. Dual quencher analysis (DQA) experiments were performed 
as previously described [123]. Briefly, samples were prepared as above, with the 
exception that in one set of samples 10% of the lipid (molar basis) was replaced with the 
quencher 10-doxyl nonadecane (10-DN). Samples contained either no 10-DN (F0) or 20 
μM 10-DN (Fdox). Similarly, peptide was added to a final concentration of 2 μM and 
allowed to equilibrate for 30 minutes. Fluorescence measurements were taken, and then 
50 μL of acrylamide was added to each F0 sample, allowed to equilibrate, and 
remeasured. After inner filter correction (only for acrylamide containing samples) and 
background subtraction, the Q-ratio was calculated as previously described [123]. 
Circular dichroism spectroscopy. Circular dichroism (CD) spectra were 
collected using Jasco J-810 spectropolarimeter. Samples contained 5 μM peptide in 0.1X 
PBS buffer or 0.1X PBS buffer with 50% trifluoroethanol (Alfa Aesar). Lipid containing 
samples consisted of 200 μM lipid vesicles with 3 μM peptide in 0.1X PBS buffer. Each 
sample had 64 scans performed with correction from background without peptide. 
Bacterial culturing. Bacteria were streaked on LB-Miller agar plates from a 
frozen glycerol stock made from the original samples shipped from CGSC (Coli Genetic 
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Stock Center, Yale University) or ATCC (American Type Culture Collection) 
(Escherichia coli D31 CGSC 5165 [124], Staphylococcus aureus ATCC 35556, 
Pseudomonas aeruginosa PA-01 ATCC 47085 [125], Acinetobacter baumannii ATCC 
19606). An overnight was prepared using a single colony of each bacterial strain into 
fresh LB broth and placed into a shaking incubator 37 C at 225 rpm for ~18 hours. After 
incubating overnight, a fresh 1:200 dilution was made in LB broth and used for the 
experiment.  
Minimal Inhibitory Concentration (MIC)/Minimal Bactericidal 
Concentration (MBC). Minimum inhibitory concentration (MIC) was performed using 
mid-log phase bacteria diluted to 5 × 105 CFU/mL. Then, 90 μL of the diluted culture 
was added to the wells of a sterile 96-well plate containing serially diluted aliquots of 
each peptide for a total volume of 100 μL. The plate was incubated at 37 C for 18 hours. 
After incubation, bacterial growth was determined by measuring OD600 using a 
Spectramax M5 multimode plate reader. Minimum bactericidal concentration (MBC) was 
performed by removing 1 μL of culture from each well of the MIC plate and plating on a 
fresh LB agar plate which was subsequently incubated overnight at 37 C. MBC was 
determined by the growth or absence of growth from each well on the agar plate. 
Lipid vesicle leakage. Lipid films were prepared as described above. A 75 mM 
stock of calcein was prepared in HEPES buffer, pH 7. The lipid film was resuspended in 
700 μL of calcein solution for a final lipid concentration of 20 mM. The resuspended 
lipid vesicle sample was subjected to seven freeze-thaw cycles by alternating between a 
liquid N2 bath and a 42 C water bath, culminating with a final thaw of the sample. The 
vesicles were then sonicated using a VCX 130 Probe sonicator (Sonics & Materials, Inc.) 
20 
 
for 1 minute, using 1 second pulses at 45% intensity. Vesicles were separated from 
unincorporated calcein by size exclusion chromatography using G25 Sephadex. The 
column was equilibrated in HBS (50 mM HEPES, 150 mM NaCl, pH 7) under gravity 
flow for approximately 1 hour before the vesicle solution was loaded onto the column. 
Upon loading, ~40 1 mL Fractions were then collected from the column. Fractions 
containing vesicles with entrapped calcein exhibited a cloudy, orange color and were 
separated from the unincorporated calcein, which has a clear yellow color. Vesicles were 
used on the same day as prepared. Vesicle concentrations/dilution factor were determined 
using a ratiometric assay with vesicles containing a known concentration of fluorescent 
lipid [126]. The two most concentrated fractions were diluted 1:1 with HBS buffer. 
Solutions were dispensed into a 96 well plate in the subsequent order: 10 μL of peptide 
with serial dilutions starting at a final concentration from 15 μM (excluding the last row 
which had 10 μL of 0.01% Acetic Acid as a negative control), 20 μL of the diluted 
vesicle fractions, and 70 μL of PBS buffer (50 mM sodium phosphate, 150 mM sodium 
chloride pH 7) for a final lipid concentration of ~200 μM. The samples were excited at 
495 nm and fluorescence emission was measured at 520 nm using a 510 nm cutoff filter 
in a Spectramax M5 (Molecular Devices) multimode plate reader. Following the initial 
reading, 20 μL of Triton X-100 was added the last row as a positive control. The plate 
was placed on a plate shaker for 1 hour at 400 rpm, shielded from light. Calcein 
fluorescence emission was then remeasured and used as the 100% leakage normalization 
value. Data reported are the average of three replicates.  
Bacterial inner membrane permeabilization assay. An overnight culture of E. 
coli D31 was prepared by inoculating a single colony into fresh LB broth and placed in a 
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37 C shaking incubator (225 rpm) for ~18 hours. Following the overnight incubation, a 
1:250 dilution of the culture to fresh LB broth was made. This was supplemented with 
100 μL of 100 mM IPTG to induce the expression of β-galactosidase. The dilution was 
incubated with shaking until an OD600 of 0.2 to 0.4 was reached. Solutions were 
dispensed into a 96 well plate in the subsequent order: 10 μL of peptide with serial 
dilutions starting a final concentration from 15 μM (excluding the last row which had 10 
μL of 0.01% acetic acid as a negative control), 56 μL Z-buffer (60 mM Na2HPO4, 40 
mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM β-mercaptoethanol, pH 7), 19 μL of 
E. coli culture, and 15 μL of 4 mg/mL ONPG dissolved in Z-buffer. Immediately 
following the addition of ONPG, absorbance was recorded at 420 nm every 5 minutes for 
90 minutes. The detergent cetyltrimethylammonium bromide was added in place of the 
peptide as a positive control. Data reported are the average of three replicates.  
Bacterial outer membrane permeabilization assay. An overnight culture of E. 
coli D31 was prepared by inoculation a single colony into fresh LB broth with 100 
μg/mL ampicillin (LB-Amp) and placed in a 37 C shaking incubator (225 rpm) for ~18 
hours. Following the overnight incubation, a 1:250 dilution of the culture to fresh LB-
Amp was made. The dilution was incubated with shaking until an OD600 of 0.2 to 0.4 
was reached. The bacterial culture was then centrifuged at 2500 rpm for 15 minutes in a 
tabletop clinical centrifuge. The supernatant was discarded and the pellet was 
resuspended in an equal amount of PBS (100 mm NaH2PO4, 200 mM NaCl, pH 7). The 
experimental samples were prepared in a 96 well plate in the subsequent order: 10 μL of 
peptide with serial dilutions starting at a final concentration from 15 μM (excluding the 
last row which had 10 μL of 0.01% acetic acid as a negative control), 80 μL of the 
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resuspended E. coli culture, and 10 μL of 50 μg/mL Nitrocefin in PBS. Immediately 
following the addition of nitrocefin, absorbance was recorded at 486 nm every 5 minutes 
for 90 minutes. The antimicrobial polymyxin B was used as a positive control. Data 
reported are the average of three replicates.  
Hemolysis assay. Hemolysis of human red blood cells (RBCs) was used to 
quantify membrane destabilization by leakage of hemoglobin. Blood was collected in 
vacutainer tubes (10 mL) with EDTA coating as an anticoagulant (provided by the 
Rowan Department of Health and Exercise Science from a fresh draw ~1 hour prior to 
use, IBC protocol 2019-11). A 7 mL aliquot of whole human blood was mixed with 7 mL 
of sterile PBS. The solution was then sedimented via centrifugation for 7 minutes at 2500 
rpm. The supernatant was removed and the pellet containing RBCs was resuspended to 
the original volume of 14 mL with PBS. This process was repeated three times. The final 
cell pellet was resuspended to a final volume of 14 mL and 90 μL of this cell suspension 
was added to all wells of a conical-bottom 96-well plate. Prior to addition of RBCs, 10 
μL of serially diluted peptide or the detergent Triton-X 100 (as a positive control) were 
added to the wells. The covered plate was placed into a shaking incubator for 60 minutes 
at 37 C while shaking (150 rpm). The conical plate was centrifuged for 10 minutes at 200 
rpm and 4 C. Subsequently, 6 μL of the supernatant was added to 94 μL of fresh PBS in 
wells of a flat-bottom plate. Analysis of hemolysis was performed by measuring 
absorbance at 415 nm using a Molecular Devices Spectramax M5 plate reader. Percent 
hemolysis was calculated based on the absorbance of each well compared to those wells 





Peptides. The original L1 sequence and all of the variants tested are listed with 
net charge, and molecular mass in Figure 1. Standard amino acid abbreviations are used 
except in the case of L1-O and L1-X, which represent the cationic substitutions of lysine 
with ornithine or di-amino-propionic acid, respectively. Solid-phase FMOC chemistry 
methods were used to synthesize all peptides. Peptides were purified using HPLC. The 
helical wheel diagrams depict the orientation of amino acids along the helical axis, also 
shown in Figure 1. In general, the original L1 sequence does not adopt a canonical 
amphiphilic helix with a hydrophobic face and a cationic face. Instead the L1 peptide in 
helical conformation exhibits a hydrophilic face, but the cationics are flank that face with 
a number of polar, uncharged, and the lone anionic group interspaced on this face. Like 
L1, numerous venom peptides do not have a strictly cationic face, but instead a polar face 
with cationic and polar uncharged residues [127-129]. 
Antimicrobial activity. Antimicrobial activity of L1 and variants were tested 
using a broth microdilution assay to determine the MIC (Table 1). All peptides exhibited 
similar (fourfold range) of activity against E. coli, and all but L1-X showed similar 
activity against A. baumannii. In contrast, the parent L1 sequence showed weak activity 
against S. aureus and P. aeruginosa, while L1-R, L1-Q, and L1-K were more effective 
against S. aureus, while L1-K and L1-Q were also very active against P. aeruginosa. The 
concentration required to kill the bacteria in solution, or MBC, was also measured by a 
plating assay after the MIC assay. The MBC values for each peptide was equal to or 
about 2x greater than the MIC. These results indicate that the L1 peptides are likely 
acting in a bactericidal mechanism, instead of a bacteriostatic mechanism. A bactericidal 
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mechanism is assumed because the bacteria is not growing when removed from the 
antimicrobial peptide solution and placed on a fresh LB-agar plate.  
 
Table 1 
MIC and MBC (µM) 
 
Note: Abbreviations: MIC, minimal inhibitory concentration; MBC, minimal bactericidal 
concentration. 
 
Solution behavior. The antimicrobial activity of most AMPs begin with the 
peptide in solution before interacting with the bacterial membrane, including the L1 
peptide. Behavior of the peptide in solution and how sequence variation can affect these 
properties play a role in the equilibrium between the free and bound states of the peptide. 
Red-Edge Excitation Spectra (REES) can be used to indicate the mobility of the Trp 
fluorophore, and yield insights into relative changes in the peptide aggregation and/or 
oligomerization [130-131]. REES results are shown in Figure 2A. All peptides displayed 
some extent of increase in the spectral barycenter as a function of excitation wavelength. 
MIC MBC MIC MBC MIC MBC MIC MBC
L1 0.94 0.94 15.00 15.00 15.00 15.00 1.88 1.88
L1-Q
0.94 0.94 1.88 1.88 7.50 7.50 0.94 1.88
L1-K
1.88 1.88 3.75 3.75 3.75 3.75 0.94 0.94
L1-R 0.94 0.94 1.88 1.88 15.00 15.00 0.94 1.88
L1-O
1.88 1.88 >15 >15 15.00 15.00 1.88 1.88
L1-X 3.75 7.50 >15 >15 15.00 >15 >15 >15
E.coli S. aureus P. aeruginosa A. baumannii
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This indicates some level of restricted motion around the Trp fluorophore. The L1, L1-K, 
L1-R, and L1-X sequences showed significant shifts in the emission, between 7 and 11 
nm at the highest excitation wavelength (307 nm), shown in the inset of Figure 2A. The 
red edge effects at this magnitude are strongly indicative of restricted motion around the 
Trp, likely caused from peptide aggregation or oligomerization.  
Quenching of Trp fluorescence by TCE was also performed to investigate the 
aggregation of L1 and variants. TCE has been shown to partition the interior of protein 
aggregates and quench Trp more efficiently at the interior of these aggregates. The Stern-
Volmer quenching constant, otherwise referred to as Ksv, is calculated from the slope of 
a linear fit to the quenching data, and was used to analyze the quenching. A higher Ksv 
value indicates increased Trp quenching. TCE quenching pattern determined by Ksv is 
shown in Figure 2B (as well as Table 2). Comparing results of TCE to REES there is 
some difference. L1-X and L1-K, which showed significant REES were also strongly 
quenched by TCE. On the other hand, L1 and L1-R, which also showed significant 
REES, were only minimally quenched by TCE. These results indicate potential 
differences in the packing or organization of the L1 solution aggregation state as a 






Figure 2. Peptide Solution Assays. Red-edge excitation shift (REES), A, and 
trichloroethanol (TCE) quenching, B. The inset in panel A depicts the total shift for each 
peptide. In both panels, L1 is shown in light blue, L1-Q in orange, L1-K in gray, L1-R in 
yellow, L1-O in dark blue, and L1-X in green. All data are averages of three samples 






































































Interactions with lipid bilayers. A critical early step in the widely accepted 
membrane-permeabilization mechanism for AMPs is the peptide interaction with lipid 
bilayers. The affinity and orientation of membrane interacting peptides has been shown to 
be impacted by bilayer thickness, headgroup composition, pH, and other factors. As 
compared to a traditional host defense peptide, L1 is a venom-derived peptide and despite 
its net positive charge there is no inherent evolutionary need for it to preferentially 
interact with anionic bilayers.  
Affinity for lipid bilayers was investigated using the environmental sensitivity of 
the naturally occurring Trp residue in the L1 sequence. When the local environment 
around the Trp shifts from more polar (aqueous solution) to less polar (surface of the 
bilayer or imbedded in bilayer core), the Trp fluorescence emission spectrum exhibits a 
shift from “red” to “blue”. The shift of the spectrum is determined by the shift in the 
spectral barycenter, or center of mass, as a function of titrated lipid vesicles [115]. The 
spectral barycenter was calculated using the intensity-weighted average over the range 
Sequence
L1 0.30 ± 0.04
L1-Q 15.35 ± 3.75
L1-K 17.63 ± 1.21
L1-R 4.23 ± 2.78
L1-O 10.97 ± 1.25






wavelengths collected [132]. The data from these binding experiments are shown in 
Figure 3, with representative spectra of the free and bound peptides shown in Figure 4. 
All variants exhibited binding to all lipid compositions tested (100% PC; 3:1 PC:PG; 3:1 
PE:PG; and 7:3 PC:Cholesterol). Higher binding affinity was shown to bilayers 
containing anionic lipids (note the difference in X-axis scaling in Panels A and C vs B 
and D in Figure 3). The peptide L1-X, containing the shortest side chain, exhibited a 
lower total shift in barycenter when completely bound in all lipids, indicating this 
substitution affects the depth of insertion into the bilayer. Although there was a lower 
total shift, it did not seem to have an effect on the general affinity for vesicles with 








Figure 3. Binding to Lipid Vesicles. Peptide binding was assayed using Trp fluorescence 
emission by titrating SUVs into a sample containing 2 μM peptide. The spectral 
barycenter was calculated after each addition of lipid vesicle and the Δbarycenter is the 
difference between the initial barycenter and that after each addition. Binding was 
assayed with, A, PC, B, 3:1 PC:PG, C, 3:1 PC:Cholesterol, and, D, 3:1 PE:PG. In all 
panels, L1 is shown in light blue, L1-Q in orange, L1-K in gray, L1-R in yellow, L1-O in 
dark blue, and L1-X in green. Note the difference in X-axis scaling for panels A and C vs 


















































































































Figure 4. Normalized Trp Emission Spectra. L1 peptide data shows before (red) and after 
(blue) interacting with lipid vesicles. Data are representative spectra after subtraction of a 
background spectrum. All samples contained 2 μM peptide and 300 μM lipid ‐ (A) PC, 
(B) PC:PG, (C) PC:Chol, (D) PE:PG. 
 
 
A series of fluorescence quenching experiments were performed to further 
investigate how the peptides interact with bilayers. Acrylamide quenching was performed 
on the peptides in solution and when bound to bilayers with various composition. Trp 
residues that are exposed to the aqueous environment are quenched efficiently by 
acrylamide. Acrylamide will not quench Trp buried in the nonpolar core of the bilayer. 
Thus, the quenchability of the Trp is directly related to its exposure to the aqueous 



















































































quenched by acrylamide under different conditions are shown in Table 3, with full 






0 is the fluorescence intensity in the absence of the quencher Q, and 
F is the fluorescence intensity in the presence of different concentration of Q. The 
constant Ksv is the product of the true quenching constant kq, and the fluorescence 
lifetime in the absence of the added quencher, τ0 [133]. In all conditions, the peptides 
show a decrease in the Ksv between aqueous and any bilayer-interacting condition, 







Figure 5. Acrylamide Quenching of L1 Peptides. Data shows L1 peptides in (A) PBS 
buffer, (B) PC vesicles, (C) PC:PG vesicles, (D) PC:Chol vesicles or (E) PE:PG vesicles. 
All samples contained 2 μM peptide and 250 μM lipid (for those with vesicles). Data are 
corrected for inner filter effects and are background subtracted. Data represent the 






















































































Note: Abbreviations: DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPG, 1,2-
dioleoyl-sn-glycero-3-phospho-(10 -rac-glycerol). Data are averages of three to six 
replicates with SD. 
 
An extension of the acrylamide quenching assay is the DQA assay, which utilizes 
acrylamide and a second, membrane-imbedded quencher, 10-DN. Although, acrylamide 
is a widely used quencher of Trp, it is unable to efficiently quench the fluorescence of 
Trp residues that are deeply submerged in the core of a bilayer [134-135]. This is why the 
novel Trp quencher, 10-DN is used alongside acrylamide. 10-DN is a highly hydrophobic 
molecule that contains a nitroxide-bearing doxyl group, which helps it strongly quench 
Trp fluorescence [136-137]. The ratio of quenching between each quencher is directly 
dependent on the Trp depth in the bilayer, which can help determine the orientation in the 
bilayer. This can qualitatively identify orientation differences between different bilayer 
compositions [123]. In the DQA assay, the more exposed the Trp residue is to the 
DOPC PC:PG PE:PG
L1 10.14 ± 1.15 2.49 ± 0.32 2.08 ± 0.27 1.89 ± 0.28 3.18 ± 1.27 1.51 ± 0.08 3.46 1.29 0.15
L1-Q 15.43 ± 0.17 1.67 ± 0.19 1.23 ± 0.01 1.52 ± 0.25 1.72 ± 0.16 1.63 ± 0.08 1.68 2.12 0.80
L1-K 16.48 ± 1.97 1.44 ± 0.13 1.07 ± 0.07 1.13 ± 0.63 1.77 ± 0.37 1.86 ± 0.01 4.09 2.51 1.78
L1-R 18.90 ± 1.49 4.64 ± 0.65 2.20 ± 0.21 0.60 ± 0.27 4.82 ± 0.81 1.46 ± 0.23 3.13 0.13 1.00
L1-O 22.68 ± 0.84 3.86 ± 0.09 2.96 ± 1.40 0.46 ± 0.63 4.54 ± 1.14 2.47 ± 0.39 4.01 1.86 1.41
L1-X 19.69 ± 4.29 7.09 ± 2.38 4.28 ± 1.17 4.72 ± 0.33 7.56 ± 0.20 4.17 ± 0.72 4.08 1.86 7.16
Q-RatioAcrylamide Quenching (Ksv (M
-1
))
PBS DOPC PC/PG PC/PG/PE PC/Chol PE/PG
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aqueous environment, the higher the Q-ratio. All Q-ratios for the L1 variants are shown 
in Table 3, with visuals in Figure 6. The Q-ratio for all peptides in DOPC were similar, 
regardless of sequence or affinity, but lower values were shown for peptides in bilayers 




Figure 6. Dual Quencher Analysis of L1 Peptides. Q-ratios were calculated for peptides 
bound to lipid vesicles containing DOPC (blue), 3:1 DOPC:DOPG (orange), or 3:1 
POPE:DOPG (grey) bilayers. The Q-ratio is calculated from the ratio of F0/F values for 
quenching by 10-doxyl nonadecane and acrylamide at fixed concentrations. F0/F values 
are averages of three to five samples.  
 
 
A fluorescent dye-release assay was used to investigate the ability of each peptide 
to permeabilize model lipid vesicles. The fluorophore calcein undergoes self-quenching 
when entrapped in the lumen of the vesicle, which exhibits low fluorescence emission 
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increasing dramatically upon bilayer permeabilization and release of the fluorophore into 
the aqueous surrounding. Peptides were exposed to lipid vesicles composed of PC, 
PG:PG, or PE:PG lipid mixtures. The percent leakage was calculated based off a 
subsequent treated of the vesicles with the bilayer disrupting detergent, Triton X-100. 
Leakage data is shown in Figure 7. The L1 peptides, in all lipid compositions, did not 
induce leakage to a large extent, however at the highest concentration tested, L1, L1-R, 
and L1-Q induced up to ~ 15% leakage in vesicle that contained PC. Interestingly, none 
of the peptides induced any discernable leakage in vesicles composed of PE:PG lipids 






Figure 7. Vesicle Permeabilization Assays. Peptide permeabilization of model lipid 
vesicles determined by dye leakage assays using calcein. Vesicles were composed of, A, 
PC, B, 3:1 PC: PG, C, 3:1 PE:PG. In all panels, data were normalized based on untreated 
vesicles (0% leakage) and vesicles treated with the detergent Triton X-100 (100% 
leakage). L1 is shown in light blue, L1-Q in orange, L1-K in gray, L1-R in yellow, L1-O 
in dark blue, and L1-X in green. All data are averages of at least three replicates and the 













































Interactions with cellular membranes. L1 peptides were investigated for the 
ability to permeabilize natural bacterial and mammalian membranes. Peptide interactions 
with model lipid vesicles is informative; however, model vesicles only replicate a small 
fraction of the complexity of natural lipid membranes which inherently contain greater 
lipid diversity, lipid asymmetry, and integral membrane proteins. Using chromogenic 
substrates of enzymes localized in the E. coli periplasmic space (nitrocefin and β-
lactamase) or cytoplasm (ONPG and β-galactosidase), the peptide effects on the 
permeability of the bacterial outer or inner membrane can be investigated. Outer 
membrane permeability is shown in Figure 8A while inner membrane permeability is 
shown in Figure 8B. Notably, these data represent snapshots of leakage after 30 minutes 
of exposure to the peptides, but full 90-minute time course data is shown in Figure 9 
(Outer membrane) and Figure 10 (Inner Membrane). All peptides exhibited the ability to 
disrupt the outer membrane in a concentration dependent manner, although L1-X only 
did so at the highest concentration tested (Figure 8A). None of the peptides induced any 
significant permeabilization of the E. coli inner membrane other than L1-R at the highest 






Figure 8. Membrane Permeabilization of E. coli. E. coli, A, outer membrane and, B, 
inner membrane permeabilization. L1 is shown in light blue, L1-Q in orange, L1-K in 
gray, L1-R in yellow, L1-O in dark blue, and L1-X in green. All data are averages of at 
least three replicates and error bars represent the SD. In some cases, error bars are smaller 












































Figure 9. E. coli Outer Membrane Permeabilization Assay. Absorbance at 486 nm 
represents the breakdown of the nitrocefin substrate by the periplasmic enzyme β‐
lactamase. Bacteria were exposed to varying concentrations of peptide and the 
corresponding colors for each panel are shown in the legend. (A) L1, (B) L1‐Q, (C) L1‐
K, (D) L1‐R, (E) L1‐O, (F) L1‐X, (G) Polymyxin B. Data represent the average and 

































































































































































Figure 10. E. coli Inner Membrane Permeabilization Assay. Absorbance at 420 nm 
represents the breakdown of the ONPG substrate by the periplasmic enzyme β‐
galactosidase. Bacteria were exposed to varying concentrations of peptide and the 
corresponding colors for each panel are shown in the legend. (A) L1, (B) L1‐Q, (C) L1‐
K, (D) L1‐R, (E) L1‐O, (F) L1‐X, (G) cetyltrimethylammonium bromide (CTAB). 
Data represent the average and SD of 3‐6 samples. 
 
15 μM 7.5 μM
3.75 μM 1.88 μM
0.94 μM 0.47 μM






























































































































































Although bacterial membrane permeabilization may be linked to antimicrobial 
activity; the L1 peptides have been shown to also permeabilize mammalian membranes. 
It is critical to understand if L1 peptides can kill host cells, which is why a hemolysis 
assay was performed. The ability to disrupt human RBC membranes was investigated 
using a hemolysis assay monitoring the release of hemoglobin after exposure to the 
peptides for 1 hour. Percent leakage was calculated based on a subsequent treatment of 
the RBCs with the bilayer disrupting detergent Triton X-100. The results are shown in 
Figure 11, with none of the L1 peptides inducing any significant disruption of RBCs, 
consistent with the previously published results on the related L2 peptide [99]. 
 
 
Figure 11. Hemolysis of Human Red Blood Cells (RBCs). Hemolysis of RBCs. Data 
were normalized based on untreated RBCs (0% hemolysis) and RBCs treated with the 
detergent Triton X-100 (100% hemolysis). L1 is shown in light blue, L1-Q in orange, L1-
K in gray, L1-R in yellow, L1-O in dark blue, and L1-X in green. All data are averages of 
at least three replicates and error bars represent the SD. In some cases, error bars are 
smaller than the size of the symbols. 
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Peptide secondary structure. The changes in amino acid sequence can 
inherently impact the structure that the peptides adopt in solution or when bound to 
membranes. Due to their small size, the L1 peptides are unlikely to adopt any tertiary 
structures, so secondary structure analysis by CD spectroscopy provides a good picture of 
the overall peptide structure. CD spectra of the L1 peptides in phosphate buffer alone or 
in buffer with 3:1 PC:PG vesicles are shown in Figure 12. In aqueous solution, all 
peptides exhibit CD spectra consistent with random / disordered structures except L1-O 
which exhibits a helical signature. When bound to lipid vesicles, all variants exhibited 










Figure 12. Circular Dichroism (CD) Spectroscopy. Spectra of all peptides were collected 
in, A, 10X diluted PBS, B, 50:50 PBS:TFE using the 10X diluted PBS, C, in the presence 
of 250 μM 3:1 PC:PG vesicles, or, D, in the presence of 250 μM 3:1 PC:Cholesterol 
vesicles. In 10X diluted PBS and 50:50 PBS:TFE, the peptide concentration was 5 μM, 
while in the presence of lipid vesicles, the peptide concentration was 3 μM. L1 is shown 
in light blue, L1-Q in orange, L1-K in gray, L1-R in yellow, L1-O in dark blue, and L1-X 





When analyzing the data, it is important to remember that the L1 peptide is 
derived from venom of an omnivorous species of ant which forages for both plants and 
insects as food [138]. Thus, the primary function of the venom peptides is not evolved for 
antimicrobial activity, but instead for offensive or defensive purposes. Additionally, 
venoms often contain multiple components which can act synergistically or act on 







































































































































different and unrelated targets [139-141]. This can be further complicated by variations in 
the diet and habitat of the insect as well as the season [142]. 
Net charge. One of the goals of the current study was to investigate the role of 
net charge on AMP properties. Although the majority of AMPs that have been studied 
have a net positive charge, many, including L1, have anionic amino acids in the 
sequence. If net positive charge is a driving force for antimicrobial activity, 
evolutionarily there would be no selective pressure to retain these anionic amino acids in 
the sequence. However, this evolutionary pressure is not as clear in venom peptides, 
which can also act as antimicrobials.  
In solution, the change of net charge from +5 to +6 or +7 did not have a 
significant impact on the REES results but were dramatically different for TCE 
quenching profiles. As the REES and TCE assays report on different aspects of Trp 
behavior (mobility and accessibility, respectively), the differences are potentially rooted 
in structural or aggregation state changes in the peptide in solution. [130-131, 143]  
The CD spectra in Figure 11 indicate these three peptides (L1, L1-Q, L1-K) are 
not helical when in solution alone. However, the amino acid substitutions to change the 
net charge of the peptide are all at position 4, while the native Trp is at position 6 (Figure 
1). These substitutions inherently likely do not impact the rotational freedom of the Trp, 
but may impact the local environment regarding polarity and/or the local packing of any 
aggregated form. Previous studies have shown that local interaction between anionic 
residues and Trp can impact spectral position and shifts [144-145], as well as peptide-
peptide interactions [146-148].  
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The effect of increasing L1 net charge had marked effects on the antimicrobial 
efficacy against S. aureus and P. aeruginosa (Table 1). Increasing the charge from +5 to 
+6 resulted in an eightfold enhancement of activity against S. aureus and a twofold 
enhancement against P. aeruginosa while further increase of net charge to +7 further 
twofold increased the efficacy against P. aeruginosa. Notably, these changes also 
enhanced activity against E. coli and A. baumannii, but the parent L1 was already quite 
effective against those strains. This is consistent with previous reports that demonstrate 
cationic charge and net charge are important determinants of antimicrobial activity in 
AMPs [143, 149-151]. These changes, however, do not appear to be driven by increased 
ability to permeabilize vesicles or native membranes. While increasing the net charge did 
result in moderate enhancements to lipid binding, this enhancement was not dependent on 
bilayer charge. These results may point to a nonpermeabilizing role of L1 peptides in 
antimicrobial activity.  
Additionally, altering the net charge on the peptide can alter the 
hydrophobic/hydrophilic balance of the sequence. Numerous studies on AMPs and 
peptidomimetic polymers have shown that this balance plays a key role in antimicrobial 
activity, cytotoxicity, and interactions with lipid bilayers [152-153]. In the peptides 
presented here, the overall hydrophobic balance is not significantly impacted as E to Q to 
K changes at position 4 are all polar. Notably, Gln is an uncharged polar residue which is 
naturally less polar than Lys, but does not result in major differences in lipid bilayer 
binding or antimicrobial activity. As such, any small changes in the 
hydrophobic/hydrophilic balance, if at all, are swamped by the change in net charge. 
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Cationic side chain identity. While the net charge of the peptide does appear to 
play some role in activity and may have strain-specific influences, previous studies on 
peptides and peptidomimetic polymers have shown that not all cationic groups behave 
identically in AMPs. Side chain length and cationic moiety identity have both been 
shown to dramatically impact characteristics of antimicrobials [154-157]. Additionally, 
the well-studied TAT sequence, originally derived from HIV, has shown a necessity for 
Arg residues to function in membrane translocation [158-159]. In the L1 background, 
switching Lys to Arg had minimal effects on MIC and MBC for all strains tested, except 
P. aeruginosa which had a marked decrease in efficacy. Interestingly, the Lys to Arg 
substitution resulted in a twofold decrease in MIC (increased efficacy) against E. coli, 
consistent with several Trp-rich sequences described by Arias et al. A number of studies 
have shown that Arg substitutions for Lys would enhance antimicrobial activity [160-
161], likely from an increased H-bonding network and ability to interact with more lipid 
molecules for each cationic moiety [162].  
Side chain length also clearly plays a role in activity and characteristics of the L1 
peptides. Reducing the side chain length by one methyl group (Lys to Orn) had little 
effect on efficacy or binding, but reduction by three methyl groups (Lys to Dap) 
dramatically increased the MIC values. This is consistent with previous results on AMPs 
and peptidomimetic polymers. However, a recent report by Hodges and coworkers has 
shown the inclusion of Dap in AMPs can cause a small reduction of antibacterial activity 
but can have a significant reduction in hemolytic activity, improving the overall 
therapeutic potential [163]. The loss of activity from shortening the length of the cationic 
side chain has been attributed to peptide penetration depth in the bilayer, the Dap side 
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chain forcing a shallower, less disruptive conformation. The DQA results indicate that the 
L1-X does appear to adopt a shallower orientation in PE:PG membranes (model of 
bacterial membranes) but shows less of a difference compared to the L1-K in PC or 
PC:PG membranes. This is consistent with the best performing sequences against E. coli 






Synergistic Interactions of Ionic Liquids and Antimicrobials to Improve Efficacy 
Introduction 
 Physiochemical properties of ionic liquids. Ionic liquids (ILs) are classified as 
novel organic salts, that exist in liquid form at room temperature [164-165]. ILs are 
composed of large organic cations or anions with alkyl chain substituents that can alter 
the hydrophobicity of the molecule. Common cations found in ILs include imidazolium 
or pyridinium, while anions include hexafluorophosphate, tetrafluoroborate, chloride, 
nitrate, and bromide [166]. ILs have been studied for a variety of applications such as 
electrochemical, industrial, and biomedical. Although there are many studies focusing on 
electrochemical applications, potential applications include drug delivery, enzymatic 
reaction enhancement, and use as biomaterials. ILs are advantageous due to their unique 
physiochemical properties such as low melting points, exceptional solvation potential, 
low volatility, and negligible vapor pressure [82]. These properties are able to be 
manipulated easily by altering their ions, alkyl chain length, or type of head group [167-
168]. Long-chain imidazolium based ILs exhibit an amphiphilic conformation with a 
charged hydrophilic head group and hydrophobic tail [169]. When in aqueous solution, 
ILs exhibit a rod-like micelle formation [170-171]. 
Ionic liquids as antimicrobials. Studies have shown prominent antibacterial activity 
of imidazolium ILs against bacteria and fungi due to their surfactant-like properties [172-
173]. However, the antimicrobial activity of each IL is dependent on the length of the 
alkyl chain. A study performed by Cook et al., had shown as the alkyl chain increased, so 
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did the antimicrobial activity. The imidazolium salts with 8 carbon atoms in the chain 
exhibited activity against a broad spectrum of both Gram-positive and Gram-negative 
bacteria. Their results concluded that antimicrobial activities correlate to ILs 
hydrophobicities (increasing alkyl chain length). However, while ILs have been shown to 
exhibit antimicrobial activity and the mechanism of action has begun to be explored, 
several key challenges must be overcome to identify whether ILs have potential as 
therapeutic agents. 
A promising method for use of ILs as antimicrobials, is to enhance efficacy of 
existing antimicrobials in combination with ILs. This study combines imidazolium 
chloride based ILs with differing alkyl tails in combination with various commercially 
available antimicrobials to examine the potential synergistic antimicrobial effects on 
various bacteria, along with human cells to determine cytotoxic limits.  
Materials and Methods 
 Ionic liquid preparation. Ionic liquids used in this study: 1-ethyl-3-
methylimidazolium chloride, [EMIM]Cl, Sigma; 1-butyl-3-methylimidazolium chloride, 
[BMIM]Cl, Sigma; 1-hexyl-3-methylimidazolium chloride, [HMIM]Cl, Alfa Aesar; and 
1-octyl-3-methylimidazolium chloride, [OMIM]Cl, Alfa Aesar; ([DMIM]Cl).  Solutions 
of IL at indicated concentration created with either PBS (Phosphate Buffer System) or 
water solvent as indicated by experiment.  
Critical micelle concentration (CMC) with tetracycline. Stocks of 2 mM 
sodium phosphate buffer, 10 ug/mL Tetracycline, and 1.0 M [OMI]Cl, and [DMI]Cl were 
prepared. DPH concentration was determined by absorbance spectroscopy using ε350 = 
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88,000 [174]. In a black, clear flat bottom 96-well plate, 50 µL of serially diluted IL was 
placed in each well. Then, calculated amount of buffer was added to each well. Once all 
wells contained buffer and IL, correct amount of tetracycline for final concentrations of 1 
µg/mL, 0.1 µg/mL, 0.01 µg/mL, or 0 µg/mL was added to the wells. Right before 
measurement, DPH (final concentration 2.5µM) was added with gentle mixing by 
pipetting to ensure no bubbles were formed. Samples were measured using λex = 358 nm 
and λem = 430 nm. 
 Bacterial culturing. Bacteria were streaked on LB-Miller agar plates from a 
frozen glycerol stock (-80°C) (Escherichia coli D31 [124], Staphylococcus aureus ATCC 
35556, Pseudomonas aeruginosa PA-01 [175], Acinetobacter baumannii ATCC 19606, 
Klebsiella pneumoniae ATCC 700603, Bacillus subtilis ATCC:6051). An overnight was 
prepared using a single colony of each bacterial strain into fresh LB broth and placed into 
a shaking incubator 37°C at 225 rpm for ~18 hours. After incubating overnight, a fresh 
1:200 dilution was made in LB broth and used for the experiment. 
Minimal Inhibitory Concentration (MIC). Same procedure performed as 
described in Chapter 2. 
Results 
Previous work has demonstrated antimicrobial effects of ILs and a strong 
correlation between increased alkyl-chain length and minimal inhibitory concentration 
(MIC) [91, 176].  In this study we evaluated both the magnitude of this antimicrobial 
effect as well the potential mechanism of actions for 3-methylimidazolium chloride ILs 




Figure 13. Imidazolium Chloride Ionic Liquids with Various Alkyl Chain Lengths 
 
Critical Micelle Concentrations (CMCs) with tetracycline. A possible mechanism 
for antimicrobial effects of ILs include the ability of the IL to act as a detergent and 
destabilize the cell membrane. An alternative hypothesis is that the amphipathic nature of 
ILs may directly impact an associated antimicrobial compound through the formation of 
micelles. Micelles are roughly spherical structures formed by amphiphilic molecules in 
which the nonpolar portion of the molecule is buried at the interior of the structure while 
the polar portions are exposed, favorably interacting with the aqueous environment.  
Previous work has shown that some imidazolium ILs can form micelles and thus if 
antimicrobials affect the CMC, it would inherently impact the antimicrobial activity 
[177]. Using a fluorescence-based assay with the environmentally sensitive fluorophore 
DPH, CMC of [OMIM]Cl and [DMIM]Cl was measured in the absence or presence of 
various concentrations of tetracycline (Figure 14).  In this assay, DPH fluorescence 
intensity increases dramatically upon formation of micelles due to DPH partitioning into 
the nonpolar core of the micelle [174].  The data shows that tetracycline has minimal 
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effect on the formation of micelles over a 100-fold concentration range tested compared 
to the no tetracycline control for both ILs examined. Thus, any effects of tetracycline in 




Figure 14. Critical Micelle Concentration (CMC) with Tetracycline. Imidazolium 
chloride ILs with various alkyl chain lengths tested in combination with tetracycline 
 
Minimum Inhibitory Concentration (MIC). Microbial inhibition effects were 
evaluated using 3-methylimidazolium chloride ILs of differing in alkyl chain length with 
six microbial strains (S. aureus, B. subtilis, P. aeruginosa, K. pneumoniae, E. coli, S. 
aureus, and A. baumanii).  In agreement with other studies, baseline MIC experiments 
suggest that alkyl chain lengths of 6, 8, and 10 exhibit independent antimicrobial effects 
with longer chain lengths exhibiting the greatest inhibition across a variety of 
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microorganisms (Table 4). MIC values, there is a direct correlation between longer alkyl 
chain lengths. For those ILs which presented with an antimicrobial effect, [HMIM]Cl, 
[OMIM]Cl, and [DMIM]Cl demonstrated a direct correlation between IL concentration, 
and ability to inhibit bacterial growth. 
 
Table 4 
MIC (mM) of ILs 
 




 Amphiphilic molecules, such as ILs, can act as antimicrobials by interacting with 
the bacterial membrane in a detergent like manner causing destabilization of the 
membrane [178]. The activity of these molecules is linked to the monomer-micelle 
equilibrium, which dramatically changes the physical and chemical properties of the 
molecules. Several lines of experiments point to the ability of imidazolium chloride-
based ILs to permeabilize cell membranes. Previous work has shown that some of these 
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imidazolium ILs can form micelles and thus if tetracycline affects the CMC, it could 
inherently impact the antimicrobial activity [177]. Micelle formation is primarily 
governed by concentration, and the concentration at which micelles form is known as the 
Critical Micelle Concentration (CMC). CMC has been shown to be influenced by salt 
concentration and other additives in solution [179]. Our results point to the fact that 
tetracycline does not significantly affect the ability of [OMIM]Cl or [DMIM]Cl to form 
micelles (Figure 14).  One possible interpretation of this finding is that tetracycline does 
not enhance the detergent-like properties of ILs action on the cellular membrane, but 
rather the addition of [OMIM]Cl or [DMIM]Cl to microbial populations acts 
independently of antimicrobial compound to elicit a membrane destabilizing effects to 
enhance the efficacy of the antimicrobial compound applied. 
Other experiments were performed to determine synergistic effects of 
imidazolium chloride based ILs and broad spectrum of commercially available 
antibiotics, along with testing human cyctotoxicity (data not shown). These tests 
consisted of a permeability assay using flow cytometry, bactericidal disc assay (zone of 
inhibition assay), and treatment of HeLa cells in the presence of ILs and tetracycline. 
When combining imidazolium chloride based ILs with an alkyl chain of 6 and 8, 
synergistic interactions with a wide-range of antimicrobials was shown. Two separate 
complementary assays were performed, a 96-well liquid culture and a zone of inhibition 
(ZOI) disc assay. The results (data not shown) exhibited that when ILs ([HMIM]Cl and 
[OMIM]Cl) and commercial antimicrobials (tetracycline (12.5 mg/mL), doxycycline 
hyclate (10 mg/mL), and clindamycin (5 mg/mL)) were used in combination, the 
necessary concentration of antimicrobial compound to inhibit growth was reduced. 
55 
 
Interestingly, while a surprisingly large number of different antimicrobials were 
enhanced by the addition of IL, many trends point to specific modes of action for synergy 
of IL and antimicrobials. One of the strongest examples of synergism, that was evident in 
various assays, was shown with addition of IL and tetracycline. The efficacy of 
doxycycline was also strongly enhanced in the ZOI experiments along with the 
antimicrobial clindamycin.  These three antibiotics are in the tetracycline family, an 
antibiotic class that inhibits protein synthesis by targeting the 30S ribosomal subunit 
[184].  It has been suggested that the limited efficacy of tetracycline, as well as the 
mechanism for antibiotic resistance, revolves around limited uptake and retention by 
bacterial strains [185].  Given the potential membrane destabilizing effect of long-alkyl 
chain ILs, it is reasonable to hypothesize that the addition of IL enhances the ability of 
this class of antibiotics to enter and maintain higher concentrations within the bacterial 
cell. 
Although ILs are known as biocompatible, non-toxic, and a green alternative, this 
classification is only realistically applied in limited concentrations. Recent reports 
highlight the toxicity of this class of molecules [186]. To examine the imidazolium based 
chloride ILs of varying alkyl chain length potential toxicity to mammalian cells, a 
combinatorial treatment of ILs and tetracycline was applied to mammalian cells. Through 
a limited approximation, the HeLa human cell line assays are the first step in identifying 
the potential human response to the combinatorial treatment of ILs and antibiotics [187]. 
When exposing human cell lines to high concentrations of ILs, toxicity is exhibited. 
However, HeLa cells treated with longer alkyl chain lengths, [OMIM]Cl, are less viable 
than when treated with [HMIM]Cl at the same final concentration. The results indicated 
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that when combining [HMIM]Cl and tetracycline, a clear synergistic response was shown 
in the reduced amount of tetracycline required to reach 70% lethality in P. aeruginosa, 
and the addition of [HMIM]Cl to HeLa cells did not increase the toxicity of tetracycline 
in culture. This suggests that the combination of imidazolium chloride based ILs with 
antimicrobials is able to reduce the amount of antibiotic necessary to combat bacterial 








Ponericin L1 Data 
The data shows that the L1 peptide is a membrane-binding peptide that can adopt 
an α-helical conformation when bound to lipid bilayers. Both the net charge and the 
identity of the cationic groups on the peptide play a significant role in antimicrobial 
activity. As net charge increased from +5 to +7 the antimicrobial activity also increased. 
The shortened cationic side chains decreased the antimicrobial activity. Decreased 
antimicrobial activity in the shortened cationic side chains may be due to the peptide not 
being able to interact with the lipid bilayer as deeply as the longer side chains. The 
peptides adopted different conformations in zwitterionic and anionic vesicles which 
somewhat correlate to the antimicrobial activity. However, the E. coli OM disruption 
correlated best with MIC. The venom peptide L1 has good potential as a selective 
antimicrobial platform due to tunable activity and low hemolytic activity. Future studies 
on the hydrophobic/hydrophilic balance and the role of the polar face of the peptide 
should provide important fundamental understanding and will help in designing a more 
effective and selective antimicrobial molecule.  
Antimicrobial Activity of Ionic Liquids Data 
 The data shows that there is an unknown synergistic interaction between 
imidazolium chloride based ILs and a broad class of antimicrobials against bacteria. Our 
results suggest that the combination of imidazolium chloride-based ILs with 
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antimicrobials is capable of reducing the amount of antibiotic necessary to combat 
bacterial growth while having little to no additional toxic effect in human cell lines. The 
mechanism of action for why the apparent enhancement of antibiotic delivery is effective 
in microbial cell populations but not mammalian cells is still unknown. One potential 
biochemical explanation is that antibiotic action is regulated by internal cellular 
concentration and that at typical treatment concentrations microbes have a baseline 
ability to exclude or remove antibiotics. Overall, the addition of ILs can enhance the 
delivery and/or retention of antimicrobials to both microbes and mammalian cells but due 
to the lack of specificity of antimicrobial targets in mammalian cells, the toxicity of the 
antimicrobial is not increased.  Future investigations will need to be performed to assess 
the underlying mechanism that protects the mammalian cells from higher concentrations 
of antibiotics while simultaneously eliciting a synergistic response in improving the 
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